These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 37377231)

  • 1. Characterization of adverse events to hydroxychloroquine, ivermectin, azithromycin and tocilizumab in patients hospitalized due to COVID-19 in a Peruvian Social Health Insurance hospital.
    Rodríguez-Tanta LY; Cachay Rojas E; Fiestas Saldarriaga F; Alva Lozada G; Fernández-Rojas P; Delgado-Escalante R
    Rev Peru Med Exp Salud Publica; 2023; 40(1):16-24. PubMed ID: 37377231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Off-label" use of hydroxychloroquine, azithromycin, lopinavir-ritonavir and chloroquine in COVID-19: A survey of cardiac adverse drug reactions by the French Network of Pharmacovigilance Centers.
    Gérard A; Romani S; Fresse A; Viard D; Parassol N; Granvuillemin A; Chouchana L; Rocher F; Drici MD;
    Therapie; 2020; 75(4):371-379. PubMed ID: 32418730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lack of efficacy of hydroxychloroquine and azithromycin in patients hospitalized for COVID-19 pneumonia: A retrospective study.
    Saib A; Amara W; Wang P; Cattan S; Dellal A; Regaieg K; Nahon S; Nallet O; Nguyen LS
    PLoS One; 2021; 16(6):e0252388. PubMed ID: 34106964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation of QT Prolongation with Hydroxychloroquine and Azithromycin for the Treatment of COVID-19.
    Seyhan AU; Doganay F; Yilmaz E; Topal NP; Ak R
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):153-157. PubMed ID: 33291194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy and safety of pharmacological interventions for the treatment of COVID-19: A systematic review and network meta-analysis.
    Kim MS; An MH; Kim WJ; Hwang TH
    PLoS Med; 2020 Dec; 17(12):e1003501. PubMed ID: 33378357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adverse drug reactions to chloroquine/hydroxychloroquine in combination with azithromycin in COVID-19 in-patients: data from intensive pharmacovigilance in Morocco, 2020.
    Aït Moussa L; Tebaa A; Alj L; Sefiani H; Meski FZ; Khattabi A; Soulaymani Bencheikh R
    Naunyn Schmiedebergs Arch Pharmacol; 2023 Dec; 396(12):3847-3856. PubMed ID: 37358793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of QT Interval Prolongation Associated With Use of Hydroxychloroquine With or Without Concomitant Azithromycin Among Hospitalized Patients Testing Positive for Coronavirus Disease 2019 (COVID-19).
    Mercuro NJ; Yen CF; Shim DJ; Maher TR; McCoy CM; Zimetbaum PJ; Gold HS
    JAMA Cardiol; 2020 Sep; 5(9):1036-1041. PubMed ID: 32936252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiovascular Safety of Azithromycin in Patients Hospitalized With COVID-19: A Prespecified Pooled Analysis of the COALITION I and COALITION II Randomized Clinical Trials.
    Furtado RHM; Barros E Silva PGM; Fonseca HAR; Serpa-Neto A; Correa TD; Guimarães HP; Pereira AJ; Olivato GB; Zampieri FG; Lisboa T; Junqueira DLM; Lapa MG; Monfardini F; Damiani LP; Echenique LS; Gebara OE; Hoffman Filho CR; Polanczyk CA; Rohde LE; Amazonas R; Machado FR; Avezum A; Azevedo LCP; Veiga VC; Rosa RG; Lopes RD; Cavalcanti AB; Berwanger O;
    Am J Cardiol; 2024 Mar; 214():18-24. PubMed ID: 38104755
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine.
    Sarayani A; Cicali B; Henriksen CH; Brown JD
    Res Social Adm Pharm; 2021 Feb; 17(2):483-486. PubMed ID: 32327397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
    Rosenberg ES; Dufort EM; Udo T; Wilberschied LA; Kumar J; Tesoriero J; Weinberg P; Kirkwood J; Muse A; DeHovitz J; Blog DS; Hutton B; Holtgrave DR; Zucker HA
    JAMA; 2020 Jun; 323(24):2493-2502. PubMed ID: 32392282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safely Administering Potential QTc Prolonging Therapy Across a Large Health Care System in the COVID-19 Era.
    Saleh M; Gabriels J; Chang D; Fishbein J; Qiu M; Mountantonakis SE; Epstein LM;
    Circ Arrhythm Electrophysiol; 2020 Nov; 13(11):e008937. PubMed ID: 33003964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Trends in drugs usage for COVID-19 during the first wave of the pandemic in a hospital in Lima, Peru].
    Castro NE; García DR; Rivera MT; Rondán-Guerrero P; García-Rojas F; Taype-Rondan A
    Rev Peru Med Exp Salud Publica; 2021; 38(4):608-614. PubMed ID: 35385014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19.
    O'Connell TF; Bradley CJ; Abbas AE; Williamson BD; Rusia A; Tawney AM; Gaines R; Schott J; Dmitrienko A; Haines DE
    JACC Clin Electrophysiol; 2021 Jan; 7(1):16-25. PubMed ID: 33478708
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical outcomes and adverse events in patients hospitalised with COVID-19, treated with off-label hydroxychloroquine and azithromycin.
    Kelly M; O'Connor R; Townsend L; Coghlan M; Relihan E; Moriarty M; Carr B; Melanophy G; Doyle C; Bannan C; O'Riordan R; Merry C; Clarke S; Bergin C
    Br J Clin Pharmacol; 2021 Mar; 87(3):1150-1154. PubMed ID: 32687645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Off-Label Use of Hydroxychloroquine in COVID-19: Analysis of Reports of Suspected Adverse Reactions From the Italian National Network of Pharmacovigilance.
    Fallani E; Cevenini F; Lazzerini PE; Verdini A; Saponara S
    J Clin Pharmacol; 2022 May; 62(5):646-655. PubMed ID: 34802170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiovascular adverse events associated with hydroxychloroquine and chloroquine: A comprehensive pharmacovigilance analysis of pre-COVID-19 reports.
    Goldman A; Bomze D; Dankner R; Hod H; Meirson T; Boursi B; Maor E
    Br J Clin Pharmacol; 2021 Mar; 87(3):1432-1442. PubMed ID: 32964535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxychloroquine and Azithromycin Combination in the Management of COVID-19 Infection: Safety and Effectiveness Challenges.
    Abou Warda AE; Tammam M; El-Gazar RA; Sarhan RM; Gaber S
    Curr Drug Saf; 2022; 17(2):143-151. PubMed ID: 34315385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. QTc prolongation in COVID-19 patients treated with hydroxychloroquine, chloroquine, azithromycin, or lopinavir/ritonavir: A systematic review and meta-analysis.
    Diaz-Arocutipa C; Brañez-Condorena A; Hernandez AV
    Pharmacoepidemiol Drug Saf; 2021 Jun; 30(6):694-706. PubMed ID: 33772933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sales of "COVID kit" drugs and adverse drug reactions reported by the Brazilian Health Regulatory Agency.
    Hentschke-Lopes M; Botton MR; Borges P; Freitas M; Mancuso ACB; Matte U
    Cad Saude Publica; 2022; 38(7):e00001022. PubMed ID: 35894360
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients.
    Eftekhar SP; Kazemi S; Barary M; Javanian M; Ebrahimpour S; Ziaei N
    Cardiovasc Ther; 2021; 2021():6683098. PubMed ID: 33688374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.